FibroGen announces positive Phase 3 results for roxadustat in chemotherapy-induced anemia in China

KYNTRA BIO, INC.

Met primary endpoint: noninferiority to erythropoietin alfa in hemoglobin change from baseline to average weeks 9-13.
Plan to file supplemental New Drug Application in China with AstraZeneca collaboration.
159 non-myeloid malignancy patients enrolled; roxadustat dosed three times weekly for 12 weeks.
Adverse event profile consistent with prior studies, supporting positive benefit-risk.
Detailed results to be presented at an upcoming medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.